Risk of Renal Cell Carcinoma Following At Least 180 Days of Exposure to Canagliflozin in U.S. Patients with Type 2 Diabetes Mellitus

This poster describes a project that investigated the risk of renal cell carcinoma in adult patients with type 2 diabetes mellitus adhering to the treatment strategies of at least 180 days of exposure to canagliflozin versus sitagliptin in the first year after initiation. It was presented at the 2026 ISPE Annual Meeting.